Back to News
Market Impact: 0.45
Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children
Source: Nasdaq
Healthcare & BiotechProduct Launches
Telix Pharmaceuticals received FDA approval for Pixclara (floretyrosine F 18/18F-FET), an amino-acid PET imaging agent for glioma, a form of brain cancer. The approval enables U.S. commercialization of a new diagnostic imaging product and is a materially positive catalyst for Telix's oncology-imaging portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
extremely positive
Sentiment Score
0.90
Ticker Sentiment
TLX0.90
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Investors Eye AI Payoff in Microsoft, Alphabet Earnings
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Apple brings touch to the Mac, reversing years-old stance on touchscreen laptop
- The 2,000-Nit OLED in Apple’s New MacBook Is a Big Deal